Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Net Income (2023 - 2025)

Zenas BioPharma (ZBIO) has 3 years of Net Income data on record, last reported at -$51.5 million in Q3 2025.

  • For Q3 2025, Net Income fell 33.4% year-over-year to -$51.5 million; the TTM value through Sep 2025 reached -$28.6 million, up 72.65%, while the annual FY2024 figure was $3.9 million, 114.95% up from the prior year.
  • Net Income reached -$51.5 million in Q3 2025 per ZBIO's latest filing, up from -$52.2 million in the prior quarter.
  • Across five years, Net Income topped out at $108.7 million in Q4 2024 and bottomed at -$52.2 million in Q2 2025.
  • Average Net Income over 3 years is -$12.2 million, with a median of -$35.8 million recorded in 2024.
  • Peak YoY movement for Net Income: crashed 208.37% in 2024, then decreased 20.77% in 2025.
  • A 3-year view of Net Income shows it stood at $35.6 million in 2023, then skyrocketed by 205.25% to $108.7 million in 2024, then tumbled by 147.36% to -$51.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Income were -$51.5 million in Q3 2025, -$52.2 million in Q2 2025, and -$33.6 million in Q1 2025.